Targeting the E2F6-TOP2A-DKK1 axis: a novel therapeutic strategy for EMT-driven hepatocellular carcinoma progression - Top-Institutions - MDSpire

Targeting the E2F6-TOP2A-DKK1 axis: a novel therapeutic strategy for EMT-driven hepatocellular carcinoma progression

  • By

  • Mindan Xing

  • Yi Lu

  • Yan Guo

  • Yantao Jiang

  • Hengqi Liu

  • Junjie Yu

  • Luyao Tong

  • Zhongyu Wang

  • Chao Li

  • Xing Chen

  • Wei Luo

  • July 2, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology

  • #2

    UT Southwestern Medical Center, Harold C. Simmons Comprehensive Cancer Center
    UT Southwestern Medical Center, Harold C. Simmons Comprehensive Cancer Center

    Dallas, TX

    Key Differentiators

    • Oncology

  • #3

    Institut Gustave Roussy
    Institut Gustave Roussy

    Villejuif, France

    Key Differentiators

    • Oncology

  • #4

    University of Paris-Saclay
    University of Paris-Saclay

    Paris, France

    Key Differentiators

    • Oncology

  • #5

    Chinese Academy of Sciences
    Chinese Academy of Sciences

    Shanghai, China

    Key Differentiators

    • Oncology

Original Source(s)

Targeting the E2F6-TOP2A-DKK1 axis: a novel therapeutic strategy for EMT-driven hepatocellular carcinoma progression

  • by Mindan Xing, Yi Lu, Yan Guo, Yantao Jiang, Hengqi Liu, Junjie Yu, Luyao Tong, Zhongyu Wang, Chao Li, Xing Chen, Wei Luo

  • July 2, 2026

Related Content

Prediction of histological grading in ductal carcinoma in situ based on mammographic signs and clinical information using machine learning models

Robot-assisted laparoscopic resection of giant pelvic solitary fibrous tumor: a case report with literature review

ASCO26: Alicia Morgans, MD, MPH, ARACOG

Dr. Alicia Morgans of Dana-Farber Cancer Institute reported at #ASCO26 that ARACOG found darolutamide was associated with less decline in cognitive testing than enzalutamide, which may help guide treatment choice.

  • July 1, 2026

  • 1 min